Extension to Study HMR1964A/3011 in Belgium

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

April 30, 2004

Conditions
Diabetes Mellitus
Interventions
DRUG

INSULIN GLARGINE

The subjects will continue the treatment with HOE 901 in the same way as they have done in the previous study. Based on the investigator's assessment and the approved SPC in Belgium/Luxembourg, the dosage can be adjusted individually. HOE 901 is to be injected once daily. HOE 901 must not be mixed with any other insulin, including regular human insulin or fast-acting insulin analogues.

Trial Locations (1)

Unknown

Sanofi-Aventis, Brussels

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY